Inventiva and SensiQ set up surface plasmon resonance (SPR) centre in France
Based in Dijon, the centre will combine Inventiva’s screening platforms and libraries with SensiQ’s instrumentation
Inventiva, a French drug discovery company, and SensiQ, a US specialist in surface plasmon resonance (SPR) technologies, have opened a European Centre of Excellence in Dijon, France, which will use SensiQ Pioneer Fragment Edition (Pioneer FE) instrumentation.
Inventiva is focused on therapeutic approaches involving transcription factors and epigenetic targets to develop innovative treatments for cancer, fibrosis and immuno-inflammatory diseases.
The company's existing pharmaceutical discovery platform will now include SensiQ SPR technology, which will strengthens its current service offering.
The new Centre also allows SensiQ to offer customers on-site demonstrations at Inventiva’s offices. Inventiva’s team will benefit from the extensive SPR experience of SensiQ's support staff.
Inventiva's co-founder and CEO, Frederic Cren, said the new Centre would provide additional technological capabilities to its partners.
'It also enhances our extensive HTS and HCS screening platforms, which, combined with our proprietary library, provide one of the most compelling offerings available on the market,' he said.
Inventiva's co-founder and CSO, Pierre Broqua, added that the SensiQ Pioneer equipment would provide a powerful tool 'to measure binding interactions and accelerate drug discovery for our partners.'
